STOML2

Across TCGA pan-cancer cohorts, STOML2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STOML2 data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher STOML2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STOML2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where STOML2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.972	0.547	.010	9	view →
CCRCC	DFS	Quartile	II,III,IV	0.830	0.198	.024	8	view →
GBM	OS	Quartile	All	0.723	0.251	.012	4	view →
LSCC	DFS	Tertile	II,III,IV	0.839	0.653	.032	1	view →
HNSC	DFS	Quartile	III,IV	0.757	0.465	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STOML2–LUAD (DFS)

Open the LUAD breakdown →